Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

869
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
869
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

325
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
325
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

2.0K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining and Measuring Cognitive Decline and Clinical Relevance.

Neurology and therapy·2026
Same author

Correction: The role of brain health and resilience in reshaping trajectories of late-life neuropsychiatric disorders.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

The role of brain health and resilience in reshaping trajectories of late-life neuropsychiatric disorders.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Associations between subjective cognitive concern, brain network connectivity, and cognitive performance in cognitively normal older adults.

Aging brain·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Resistance and resilience to Alzheimer's disease in Down syndrome.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Apr 6, 2026

Place and Response Learning in the Open-field Tower Maze
08:31

Place and Response Learning in the Open-field Tower Maze

Published on: October 28, 2015

11.0K

Estrogen-cholinergic interactions: Implications for cognitive aging.

Paul Newhouse1, Julie Dumas2

  • 1Center for Cognitive Medicine, Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA; Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System, Nashville, TN, USA.

Hormones and Behavior
|July 19, 2015
PubMed
Summary
This summary is machine-generated.

Estradiol supports attention and memory by interacting with the brain's cholinergic system. This research explores these estrogen-cholinergic interactions in humans, offering insights into cognitive aging.

Keywords:
AcetylcholineAttentionBrain imagingCognitive performanceEstradiolMemory

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats
09:07

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats

Published on: February 23, 2015

14.3K

Related Experiment Videos

Last Updated: Apr 6, 2026

Place and Response Learning in the Open-field Tower Maze
08:31

Place and Response Learning in the Open-field Tower Maze

Published on: October 28, 2015

11.0K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats
09:07

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats

Published on: February 23, 2015

14.3K

Area of Science:

  • Neurobiology
  • Cognitive Science
  • Endocrinology

Background:

  • Estrogen's impact on human cognition is well-documented, but its neurobiological underpinnings, particularly the cholinergic system's role, require further study.
  • The central nervous system (CNS) cholinergic system is crucial for cognitive functions like attention, learning, and memory.
  • Estradiol is hypothesized to maintain attention and memory, domains modulated by the cholinergic system.

Purpose of the Study:

  • To review human studies investigating the interaction between estradiol and the cholinergic system in relation to cognitive function.
  • To extend preclinical findings on estrogen-cholinergic pathways to human subjects.
  • To explore the implications for cognitive aging and potential therapeutic strategies.

Main Methods:

  • Review of human studies examining estradiol and cholinergic antagonist effects on cognition in older women.
  • Functional brain imaging to investigate neural correlates of estrogen-cholinergic interactions.
  • Studies on selective estrogen receptor modulators (e.g., tamoxifen) and their effects on cholinergic-mediated cognition.

Main Results:

  • Estradiol plays a role in maintaining attention and memory, consistent with its interaction with the cholinergic system.
  • Evidence suggests that basal forebrain cholinergic systems are dependent on estradiol for optimal functioning.
  • Selective estrogen receptor modulators can influence cognitive performance mediated by the cholinergic system.

Conclusions:

  • Human studies support the hypothesis of significant estrogen-cholinergic interactions influencing cognition.
  • These interactions are relevant to understanding cognitive aging and developing interventions.
  • Exploiting estrogen-cholinergic pathways may offer prophylactic and therapeutic benefits for cognitive health.